1. Patient delay in TIA: a systematic review

   • L. Servaas Dolmans
   • Arno W. Hoes
   • Frans H. Rutten

   Review Open access 19 July 2018 Pages: 1051 - 1058

   

2. Cluster headache: pathophysiology, diagnosis and treatment

   • Srdjan Ljubisavljevic
   • Jasna Zidverc Trajkovic

   Review 17 August 2018 Pages: 1059 - 1066

3. Frequent central nervous system, pachymeningeal and plexus MRI changes in POEMS syndrome

   • Oliver J. Ziff
   • Chandrashekar Hoskote
   • Michael P. T. Lunn

   Original Communication Open access 12 February 2019 Pages: 1067 - 1072

   

4. Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment

   • Quentin Riller
   • Camille Cotteret
   • Fleur Cohen Aubart

   Original Communication 09 February 2019 Pages: 1073 - 1078

   

5. Hereditary primary lateral sclerosis and progressive nonfluent aphasia

   • José Gazulla
   • Isidro Ferrer
   • José Berciano

   Original Communication 05 March 2019 Pages: 1079 - 1090

   

6. Cerebral microbleeds are associated with cognitive decline early after ischemic stroke

   • Nicolas Christ
   • Viola Mocke
   • Felix Fluri

   Original Communication 14 February 2019 Pages: 1091 - 1094

7. Multi-database study of multiple sclerosis: identification, validation and description of MS patients in two countries

   • Rebecca Persson
   • Sally Lee
   • Susan Jick

   Original Communication Open access 18 February 2019 Pages: 1095 - 1106

8. Congenital myasthenic syndrome caused by novel COL13A1 mutations

   • Marina Dusl
   • Teresa Moreno
   • Jan Senderek

   Original Communication 14 February 2019 Pages: 1107 - 1112

   

9. Deep brain stimulation of the subthalamic nucleus and the temporal discounting of primary and secondary rewards

   • M. Aiello
   • D. Terenzi
   • R. I. Rumiati

   Original Communication 14 February 2019 Pages: 1113 - 1119

   

10. Parkinson’s disease among migrants in Europe: estimating the magnitude of an emerging phenomenon

    • Marco Canevelli
    • Giuseppe Bruno
    • Giovanni Fabbrini

    Original Communication 14 February 2019 Pages: 1120 - 1126

    

11. Relationship between muscle inflammation and fat replacement assessed by MRI in facioscapulohumeral muscular dystrophy

    • Julia R. Dahlqvist
    • Grete Andersen
    • John Vissing

    Original Communication 18 February 2019 Pages: 1127 - 1135

    

12. Writing, reading, and speaking in blepharospasm

    • Gina Ferrazzano
    • Antonella Conte
    • Giovanni Fabbrini

    Original Communication 19 February 2019 Pages: 1136 - 1140

13. Blood pressure circadian rhythm alterations in alpha-synucleinopathies

    • Fabrizio Vallelonga
    • Cristina Di Stefano
    • Simona Maule

    Original Communication 19 February 2019 Pages: 1141 - 1152

    

14. Misdiagnoses and delay of diagnoses in Moyamoya angiopathy—a large Caucasian case series

    • Jonas Graf
    • Jan Claudius Schwitalla
    • Markus Kraemer

    Original Communication 25 February 2019 Pages: 1153 - 1159

    

15. Color perception impairment following optic neuritis and its association with retinal atrophy

    • Netta Levin
    • Michael Devereux
    • Ari Green

    Original Communication 20 February 2019 Pages: 1160 - 1166

    

16. Dissecting the neurological phenotype in children with callosal agenesis, interhemispheric cysts and malformations of cortical development

    • Sara Uccella
    • Andrea Accogli
    • Mariasavina Severino

    Original Communication 22 February 2019 Pages: 1167 - 1181

    

17. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis

    • Benjamin Turner
    • Bruce A. C. Cree
    • Stephen L. Hauser

    Original Communication Open access 28 February 2019 Pages: 1182 - 1193

    

18. Lifestyles correlate with stroke recurrence in Chinese inpatients with first-ever acute ischemic stroke

    • Zhi-Xin Huang
    • Xiao-Ling Lin
    • Xin-Tong Liu

    Original Communication 19 February 2019 Pages: 1194 - 1202

    

19. Predicting cognitive decline with non-clinical markers in Parkinson’s disease (PRECODE-2)

    • Tayyabah Yousaf
    • Gennaro Pagano
    • Marios Politis

    Original Communication Open access 28 February 2019 Pages: 1203 - 1210

    

20. Efficacy and safety of leuprorelin acetate for subjects with spinal and bulbar muscular atrophy: pooled analyses of two randomized-controlled trials

    • Atsushi Hashizume
    • Masahisa Katsuno
    • JASMITT study group

    Original Communication 07 March 2019 Pages: 1211 - 1221

    

21. Joint impact of seven risk factors on incident dementia in elderly Japanese: the Ohsaki Cohort 2006 Study

    • Yumika Kotaki
    • Yasutake Tomata
    • Ichiro Tsuji

    Original Communication 02 March 2019 Pages: 1222 - 1229

    

22. Juxtacortical lesions are associated with seizures in cerebral small vessel disease

    • Sebastian Stösser
    • Stefanie Böckler
    • Hermann Neugebauer

    Original Communication 26 February 2019 Pages: 1230 - 1235

    

23. Postural control during galvanic vestibular stimulation in patients with persistent perceptual–postural dizziness

    • Josephin Woll
    • Andreas Sprenger
    • Christoph Helmchen

    Original Communication 26 February 2019 Pages: 1236 - 1249

    

24. Effect of small-vessel disease on cognitive trajectory after atrial fibrillation-related ischaemic stroke or  TIA

    • Gargi Banerjee
    • Edgar Chan
    • The CROMIS-2 collaborators

    Original Communication Open access 07 March 2019 Pages: 1250 - 1259

    

25. Speech treatment improves dysarthria in multisystemic ataxia: a rater-blinded, controlled pilot-study in ARSACS

    • Adam P. Vogel
    • Lisa H. Stoll
    • Matthis Synofzik

    Original Communication 06 March 2019 Pages: 1260 - 1266

    

26. Resolution of apathy after dorsal instead of ventral subthalamic deep brain stimulation for Parkinson’s disease

    • Thomas J. Zoon
    • Rob M. de Bie
    • Martijn Figee

    Letter to the Editors 20 February 2019 Pages: 1267 - 1269

    

27. Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease

    • Stephan Richter
    • Bert Wagner
    • Elisabeth Gulowsen Celius

    Letter to the Editors 25 February 2019 Pages: 1270 - 1271

28. Defining metronidazole-induced encephalopathy

    • Akira Kuriyama
    • Jeffrey L. Jackson

    Letter to the Editors 12 March 2019 Pages: 1272 - 1273

29. Crossed aphasia confirmed by fMRI in a case with nonfluent variant of primary progressive aphasia carrying a GRN mutation

    • Elisa Canu
    • Valentina Bessi
    • Federica Agosta

    Short Commentary 29 March 2019 Pages: 1274 - 1279

    

30. Neurological update: MOG antibody disease

    • Ray Wynford-Thomas
    • Anu Jacob
    • Valentina Tomassini

    Neurological Update Open access 19 December 2018 Pages: 1280 - 1286

    

31. Autoimmune encephalitis: frequency and prognosis

    • A. Al-Ansari
    • N. P. Robertson

    Journal club Open access 15 March 2019 Pages: 1287 - 1289

32. Pierre Mollaret (1898–1987)

    • Bruno Kusznir Vitturi
    • Wilson Luiz Sanvito

    Pioneers in Neurology 10 August 2018 Pages: 1290 - 1291